BCAX
Bicara Therapeutics Inc.
$18.04
+$1.86(+11.50%)
75
Overall
60
Value
90
Tech
--
Quality
Market Cap
$852.95M
Volume
779.88K
52W Range
$7.80 - $22.68
Target Price
$32.57
Company Overview
| Mkt Cap | $852.95M | Price | $18.04 |
| Volume | 779.88K | Change | +11.50% |
| P/E Ratio | -12.5 | Open | $16.13 |
| Revenue | -- | Prev Close | $16.18 |
| Net Income | $-68.0M | 52W Range | $7.80 - $22.68 |
| Div Yield | N/A | Target | $32.57 |
| Overall | 75 | Value | 60 |
| Quality | -- | Technical | 90 |
No chart data available
About Bicara Therapeutics Inc.
Bicara Therapeutics Inc., a clinical-stage biopharmaceutical company, engages in the development of bifunctional therapies for solid tumors. The company's lead program is ficerafusp alfa, a bifunctional antibody that combines an epidermal growth factor receptor (EGFR) directed monoclonal antibody with a domain that binds to human transforming growth factor beta (TGF-b) for the treatment of solid tumors. The company was incorporated in 2018 and is based in Boston, Massachusetts.
Latest News
Wells Fargo Sticks to Its Hold Rating for Bicara Therapeutics Inc. (BCAX)
TipRanks Auto-Generated Intelligence Newsdesk•12 days ago
H.C. Wainwright Remains a Buy on Bicara Therapeutics Inc. (BCAX)
TipRanks Auto-Generated Intelligence Newsdesk•13 days ago
Analysts Are Bullish on These Healthcare Stocks: Bicara Therapeutics Inc. (BCAX), Editas Medicine (EDIT)
Brian Anderson•13 days ago
Bicara Therapeutics’ FORTIFI-HN01 Study: A Promising Step in Cancer Treatment
TipRanks Clinical-Trials-Auto-Generated Newsdesk•a month ago
Bicara Therapeutics’ Innovative Approach to EGFR-Driven Tumors: A Clinical Study Update
TipRanks Clinical-Trials-Auto-Generated Newsdesk•a month ago
| A | B | C | D | |
|---|---|---|---|---|
| 1 | Symbol | Price | Change | Vol |
| 2 | BCAX | $18.04 | +11.5% | 779.88K |
| 3 | ||||
| 4 | ||||
| 5 | ||||
| 6 |
Get Bicara Therapeutics Inc. Data in Excel
Stream real-time data directly to your spreadsheets
BUY NOW